These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22890768)

  • 21. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
    Verweij PE; Te Dorsthorst DT; Rijs AJ; De Vries-Hospers HG; Meis JF
    J Clin Microbiol; 2002 Jul; 40(7):2648-50. PubMed ID: 12089298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
    MacCallum DM; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azole preexposure affects the Aspergillus fumigatus population in patients.
    Alanio A; Cabaret O; Sitterlé E; Costa JM; Brisse S; Cordonnier C; Bretagne S
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4948-50. PubMed ID: 22710122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
    van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
    Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation is associated with voriconazole trough concentrations.
    van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
    Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
    Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voriconazole. UK 109496.
    Drugs R D; 1999 Feb; 1(2):187-8. PubMed ID: 10566023
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.
    Escribano P; Recio S; Peláez T; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2011 May; 55(5):2460-2. PubMed ID: 21321141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.
    Salas V; Pastor FJ; Calvo E; Sutton DA; Fothergill AW; Guarro J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1404-8. PubMed ID: 23295918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
    Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.
    Henry ME; Bolo NR; Zuo CS; Villafuerte RA; Cayetano K; Glue P; Damle BD; Andrews E; Lauriat TL; Rana NS; Churchill JH; Renshaw PF
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5271-6. PubMed ID: 23939898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of voriconazole in adults.
    Hope WW
    Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.
    Dannaoui E; Garcia-Hermoso D; Naccache JM; Meneau I; Sanglard D; Bouges-Michel C; Valeyre D; Lortholary O
    J Med Microbiol; 2006 Oct; 55(Pt 10):1457-1459. PubMed ID: 17005798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Voriconazole-medicalneeds, evidence, potential for the future].
    Shirasawa H; Nagino K
    Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):223-8. PubMed ID: 16282963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis.
    Pelaez T; Gijón P; Bunsow E; Bouza E; Sánchez-Yebra W; Valerio M; Gama B; Cuenca-Estrella M; Mellado E
    J Clin Microbiol; 2012 Jul; 50(7):2531-4. PubMed ID: 22573589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
    Chandrasekar PH; Cutright J; Manavathu E
    J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.